The Strategic RoadmapBack to Executive Summary
Operational Timeline: Q3 2025 to 2027+
AI Cardia is transitioning from proven traction to a Canada-ready regulatory and clinical scale model with a quarter-by-quarter execution framework.
Q3-Q4 2025
Foundation Reset and Pilot Validation
- Technical Redesign (v2.0 Canada-Ready): Re-architect platform components to align with Canadian privacy, security, and operational requirements while preserving rapid inference performance and multilingual usability.
- Closed Beta Pilots (GTA Clinics + Settlement Agencies): Launch controlled pilots with frontline clinic partners in the Greater Toronto Area and immigrant-serving organizations to validate workflow fit, interpretation utility, and patient communication impact in high-need populations.
- Primary Outcomes: Demonstrate point-of-care feasibility in real frontline settings; Collect structured clinician and patient feedback for product hardening; Build evidence narrative for regulatory and partnership progression.
Q1-Q2 2026
Market Entry and Regulatory Initiation
- Android Freemium Launch: Deploy a scalable Android entry channel to accelerate acquisition and real-world usage data while preserving a clinician-relevant experience layer.
- User Growth Target: Reach early-access users through focused distribution and conversion strategy tied to care-access pain points.
- Regulatory Milestone: Initiate Health Canada regulatory-readiness process, aligning product documentation, quality artifacts, and operating procedures with formal compliance pathways.
- Execution Priority: Balance growth velocity with governance readiness so commercialization and compliance mature in parallel rather than sequence.
Q3-Q4 2026
Platform Expansion and Institutional Credibility
- iOS Launch: Complete cross-platform availability to remove device friction and expand adoption in both clinical and caregiver segments.
- Scale Targets: Surpass 25K users and achieve $5K MRR with disciplined unit-economics monitoring.
- Partnership and Funding Milestones: Secure non-dilutive grants to support evidence generation and product acceleration; Formalize a Canadian clinical validation partnership to strengthen institutional trust and long-term procurement readiness.
2027+
Edge Intelligence and International Expansion
- Edge AI Optimization: Advance on-device processing to strengthen offline functionality, privacy posture, and resilience in low-connectivity settings.
- Smartwatch/Wearable API Integrations: Extend the platform from episodic interpretation to continuous ecosystem interoperability via wearable data pathways.
- Geographic Expansion (EU/MENA): Leverage validated Canadian operating model and prior regional traction to execute selective expansion, prioritizing markets with similar access inequities and digital-care demand profiles.